Search

Your search keyword '"Amorim, Sandy"' showing total 47 results
Start Over Author "Amorim, Sandy"
47 results on '"Amorim, Sandy"'

1. Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort

Author

Ghesquières, Hervé, Cherblanc, Fanny, Belot, Aurélien, Micon, Sophie, Bouabdallah, Krimo K., Esnault, Cyril, Fornecker, Luc-Matthieu, Thokagevistk, Katia, Bonjour, Maxime, Bijou, Fontanet, Haioun, Corinne, Morineau, Nadine, Ysebaert, Loïc, Damaj, Gandhi, Tessoulin, Benoit, Guidez, Stéphanie, Morschhauser, Franck, Thiéblemont, Catherine, Chauchet, Adrien, Gressin, Rémy, Jardin, Fabrice, Fruchart, Christophe, Labouré, Gaëlle, Fouillet, Ludovic, Lionne-Huyghe, Pauline, Bonnet, Antoine, Lebras, Laure, Amorim, Sandy, Leyronnas, Cécile, Olivier, Gaelle, Guieze, Romain, Houot, Roch, Launay, Vincent, Drénou, Bernard, Fitoussi, Olivier, Detourmignies, Laurence, Abraham, Julie, Soussain, Carole, Lachenal, Florence, Pica, Gian Matteo, Fogarty, Patrick, Cony-Makhoul, Pascale, Bernier, Adeline, Le Guyader-Peyrou, Sandra, Monnereau, Alain, Boissard, Frédéric, Rossi, Cédric, and Camus, Vincent

Published
2024
Full Text
View/download PDF

2. Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

Author

Driessen, Julia, Kersten, Marie José, Visser, Lydia, van den Berg, Anke, Tonino, Sanne H., Zijlstra, Josée M., Lugtenburg, Pieternella J., Morschhauser, Franck, Hutchings, Martin, Amorim, Sandy, Gastinne, Thomas, Nijland, Marcel, Zwezerijnen, Gerben J. C., Boellaard, Ronald, de Vet, Henrica C. W., Arens, Anne I. J., Valkema, Roelf, Liu, Roberto D. K., Drees, Esther E. E., de Jong, Daphne, Plattel, Wouter J., and Diepstra, Arjan

Published
2022
Full Text
View/download PDF

3. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group

Author

Aubrais, Raphaelle, Bouabdallah, Krimo, Chartier, Loic, Herbaux, Charles, Banos, Anne, Brice, Pauline, Sibon, David, Schiano, Jean Marc, Cluzeau, Thomas, Laribi, Kamel, Le Calloch, Ronan, Bellal, Mathieu, Delapierre, Baptiste, Daguindau, Nicolas, Amorim, Sandy, Agbetiafa, Kossi, Chauchet, Adrien, Besson, Caroline, Durot, Eric, Bonnet, Christophe, Fouillet, Ludovic, Bijou, Fontanet, Tournilhac, Olivier, Gaulard, Philippe, Parrens, Marie-Cécile, and Damaj, Gandhi

Published
2023
Full Text
View/download PDF

4. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort

Author

Bouclet, Florian, Calleja, Anne, Dilhuydy, Marie-Sarah, Véronèse, Lauren, Pereira, Bruno, Amorim, Sandy, Cymbalista, Florence, Herbaux, Charles, de Guibert, Sophie, Roos-Weil, Damien, Hivert, Bénédicte, Aurran, Thérèse, Dupuis, Jehan, Blouet, Anaise, Tchernonog, Emmanuelle, Laribi, Kamel, Dmytruck, Nataliya, Morel, Pierre, Michallet, Anne-Sophie, Dartigeas, Caroline, Tournilhac, Olivier, Nguyen-Khac, Florence, Delmer, Alain, Feugier, Pierre, Ysebaert, Loïc, and Guièze, Romain

Published
2021
Full Text
View/download PDF

5. Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort

Author

Ghesquieres, Herve, primary, Cherblanc, Fanny, additional, Belot, Aurelien, additional, Micon, Sophie, additional, Bouabdallah, Krimo, additional, Esnault, Cyril, additional, Fornecker, Luc-Matthieu, additional, Thokagevistk, Katia, additional, Bonjour, Maxime, additional, Bijou, Fontanet, additional, Haioun, Corinne, additional, Morineau, Nadine, additional, Ysebaert, Loïc, additional, Damaj, Gandhi, additional, Tessoulin, Benoit, additional, Guidez, Stéphanie, additional, Morschhauser, Franck, additional, Thieblemont, Catherine, additional, Chauchet, Adrien, additional, Gressin, Remy, additional, Jardin, Fabrice, additional, Fruchart, Christophe, additional, Labouré, Gaelle, additional, Fouillet, Ludovic, additional, Lionne-Huyghe, Pauline, additional, Bonnet, Antoine, additional, Lebras, Laure, additional, Amorim, Sandy, additional, Leyronnas, Cecile, additional, Olivier, Gaelle, additional, Guieze, Romain, additional, Houot, Roch, additional, Launay, Vincent, additional, Drénou, Bernard, additional, Fitoussi, Olivier, additional, Detourmignies, Laurence, additional, Abraham, Julie, additional, Soussain, Carole, additional, Lachenal, Florence, additional, Pica, Gian Matteo, additional, Fogarty, Patrick, additional, Cony-Makhoul, Pascale, additional, Bernier, Adeline, additional, Le Guyader-Peyrou, Sandra, additional, Monnereau, Alain, additional, Boissard, Frédéric, additional, Rossi, Cédric, additional, and Camus, Vincent, additional

Published
2023
Full Text
View/download PDF

6. Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients

Author

Milcent, Benoit, Josseaume, Nathalie, Riller, Quentin, Giglioli, Ilenia, Rabia, Emilia, Deligne, Claire, Latouche, Jean-Baptiste, Hamieh, Mohamad, Couture, Alexandre, Toutirais, Olivier, Lone, Yu-Chun, Jeger-Madiot, Raphaël, Graff-Dubois, Stéphanie, Amorim, Sandy, Loiseau, Pascale, Toubert, Antoine, Brice, Pauline, Thieblemont, Catherine, Teillaud, Jean-Luc, and Sibéril, Sophie

Published
2019
Full Text
View/download PDF

7. BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Author

Cornillon, Jérôme, Daguenet, Elisabeth, Bay, Jacques-Olivier, Chauchet, Adrien, Salles, Gilles, Contentin, Nathalie, Nicolas-Virelizier, Emmanuelle, Mercier, Mélanie, Vallet, Nicolas, Alexis, Magda, Chrétien, Marie-Lorraine, Cluzeau, Thomas, Huynh, Anne, Himberlin, Chantal, Dorvaux, Véronique, Amorim, Sandy, Lejeune, Caroline, de Latour, Régis Peffault, and Gyan, Emmanuel

Published
2019
Full Text
View/download PDF

10. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA

Author

Aubrais, Raphaelle, primary, Bouabdallah, Krimo, additional, chartier, loic, additional, Herbaux, Charles, additional, Banos, Anne, additional, Brice, Pauline, additional, Sibon, David, additional, Schiano, Jean Marc, additional, Cluzeau, Thomas, additional, Laribi, Kamel, additional, LE CALLOCH, Ronan, additional, bellal, Mathieu, additional, Delapierre, Baptiste, additional, daguindau, nicolas, additional, Amorim, Sandy, additional, Agbetiafa, Kossi, additional, Chauchet, Adrien, additional, besson, caroline, additional, Durot, Eric, additional, Bonnet, Christophe, additional, Fouillet, Ludovic, additional, Bijou, Fontanet, additional, Tournilhac, Olivier, additional, Gaulard, Philippe, additional, Parrens, Marie-Cécile, additional, and Damaj, Gandhi, additional

Published
2022
Full Text
View/download PDF

12. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

Author

Amorim, Sandy, Stathis, Anastasios, Gleeson, Mary, Iyengar, Sunil, Magarotto, Valeria, Leleu, Xavier, Morschhauser, Franck, Karlin, Lionel, Broussais, Florence, Rezai, Keyvan, Herait, Patrice, Kahatt, Carmen, Lokiec, François, Salles, Gilles, Facon, Thierry, Palumbo, Antonio, Cunningham, David, Zucca, Emanuele, and Thieblemont, Catherine

Published
2016
Full Text
View/download PDF

13. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study

Author

Dupuis, Jehan, Morschhauser, Franck, Ghesquières, Hervé, Tilly, Hervé, Casasnovas, Olivier, Thieblemont, Catherine, Ribrag, Vincent, Bossard, Céline, Bras, Fabien Le, Bachy, Emmanuel, Hivert, Bénédicte, Nicolas-Virelizier, Emmanuelle, Jardin, Fabrice, Bastie, Jean-Noel, Amorim, Sandy, Lazarovici, Julien, Martin, Antoine, and Coiffier, Bertrand

Published
2015
Full Text
View/download PDF

14. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

Author

Younes, Anas, Thieblemont, Catherine, Morschhauser, Franck, Flinn, Ian, Friedberg, Jonathan W, Amorim, Sandy, Hivert, Benedicte, Westin, Jason, Vermeulen, Jessica, Bandyopadhyay, Nibedita, de Vries, Ronald, Balasubramanian, Sriram, Hellemans, Peter, Smit, Johan W, Fourneau, Nele, and Oki, Yasuhiro

Published
2014
Full Text
View/download PDF

16. Salvage Therapy with Brentuximab-Vedotin and Bendamustine for Patients with Relapsed/Refractory T Cell Lymphoma. a Multicenter and Retrospective Study

Author

Bouabdallah, Krimo, primary, Aubrais, Raphaëlle, additional, Chartier, Loïc, additional, Herbaux, Charles, additional, Banos, Anne, additional, Brice, Pauline, additional, Ochmann, Marlene, additional, Sibon, David, additional, Schiano De Colella, Jean Marc, additional, Cluzeau, Thomas, additional, Laribi, Kamel, additional, Le Calloch, Ronan, additional, Bellal, Mathieu, additional, Daguindau, Nicolas, additional, Amorim, Sandy, additional, Agbetiafa, Kossi, additional, Chauchet, Adrien, additional, Hammami, Marwa, additional, Durot, Eric, additional, Bonnet, Christophe, additional, Robles, Margot, additional, Fouillet, Ludovic, additional, Bijou, Fontanet, additional, Tournilhac, Olivier, additional, Gaulard, Philippe, additional, Parrens, Marie, additional, Milpied, Noel-Jean, additional, and Damaj, Gandhi Laurent, additional

Published
2021
Full Text
View/download PDF

17. Nivolumab First-Line Therapy for Elderly, Frail Hodgkin Lymphoma Patients: Niviniho, a Lysa Phase II Study

Author

Lazarovici, Julien, primary, Amorim, Sandy, additional, Bouabdallah, Krimo, additional, Guidez, Stéphanie, additional, Molina, Lysiane, additional, Morschhauser, Franck, additional, Gac, Anne-Claire, additional, Gastinne, Thomas, additional, Laribi, Kamel, additional, Launay, Vincent, additional, Slama, Bohrane, additional, Belmecheri, Nawel, additional, Casasnovas, René-Olivier, additional, Corby, Anne, additional, Durot, Eric, additional, Feugier, Pierre, additional, Nicolas-Virelizier, Emmanuelle, additional, Sibon, David, additional, Berriolo-Riedinger, Alina, additional, Edeline, Veronique, additional, Vander Borght, Thierry, additional, Damotte, Diane, additional, Traverse-Glehen, Alexandra, additional, Andre, Marc, additional, and Ribrag, Vincent, additional

Published
2021
Full Text
View/download PDF

18. Efficacy of ibrutinib in the treatment of Bing–Neel syndrome

Author

Cabannes-Hamy, Aurélie, Lemal, Richard, Goldwirt, Lauriane, Poulain, Stéphanie, Amorim, Sandy, Pérignon, Renan, Berger, Juliette, Brice, Pauline, De Kerviler, Eric, Bay, Jacques-Olivier, Sauvageon, Helene, Beldjord, Kheira, Mourah, Samia, Tournilhac, Olivier, and Thieblemont, Catherine

Published
2016
Full Text
View/download PDF

19. Azole resistance of Aspergillus fumigatus in immunocompromised patients with invasive Aspergillosis

Author

Alanio, Alexandre, Denis, Blandine, Hamane, Samia, Raffoux, Emmanuel, de Latour, Regis Peffault, Menotti, Jean, Amorim, Sandy, Touratier, Sophie, Bergeron, Anne, and Bretagne, Stephane

Subjects
Aspergillus -- Physiological aspects -- Research, Microbial drug resistance -- Research, Aspergillosis -- Drug therapy -- Research, Health
Abstract

To the Editor: First-line antifungal therapy for invasive aspergillosis (IA) is voriconazole, which is challenged by the emergence of azole resistance (1). A recent article reported a 3.2% prevalence of [...]

Published
2016

21. Outcome of Patients Receiving Venetoclax for Chronic Lymphocytic Leukemia (CLL) in Real-Life Clinical Practice: Results of the French ATU Program on Behalf of the Filo Group

Author

Bouclet, Florian, primary, Calleja, Anne, additional, Dilhuydy, Marie-Sarah, additional, Amorim, Sandy, additional, Cymbalista, Florence, additional, Herbaux, Charles, additional, de Guibert, Sophie, additional, Roos-Weil, Damien, additional, Hivert, Benedicte, additional, Aurran, Thérèse, additional, Dupuis, Jehan, additional, Blouet, Anaise, additional, Tchernonog, Emmanuelle, additional, Laribi, Kamel, additional, Dmytruk, Natalia, additional, Morel, Pierre, additional, Michallet, Anne-Sophie, additional, Dartigeas, Caroline, additional, Farnault, Laure, additional, Lavaud, Anne, additional, Plantier, Isabelle, additional, Bay, Jacques-Olivier, additional, Tournilhac, Olivier, additional, Delmer, Alain Jacques, additional, Feugier, Pierre, additional, Ysebaert, Loic, additional, and Guieze, Romain, additional

Published
2018
Full Text
View/download PDF

22. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study

Author

Iannitto, Emilio, primary, Bellei, Monica, additional, Amorim, Sandy, additional, Ferreri, Andrés J. M., additional, Marcheselli, Luigi, additional, Cesaretti, Marina, additional, Haioun, Corinne, additional, Mancuso, Salvatrice, additional, Bouabdallah, Krimo, additional, Gressin, Remy, additional, Tripodo, Claudio, additional, Traverse‐Glehen, Alexandra, additional, Baseggio, Lucile, additional, Zupo, Simonetta, additional, Stelitano, Caterina, additional, Castagnari, Barbara, additional, Patti, Caterina, additional, Alvarez, Isabel, additional, Liberati, Anna Marina, additional, Merli, Michele, additional, Gini, Guido, additional, Cabras, Maria Giuseppina, additional, Dupuis, Jean, additional, Tessoulin, Benoit, additional, Perrot, Aurore, additional, Re, Francesca, additional, Palombi, Francesca, additional, Gulino, Alessandro, additional, Zucca, Emanuele, additional, Federico, Massimo, additional, and Thieblemont, Catherine, additional

Published
2018
Full Text
View/download PDF

24. Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study

Author

Deau, Benedicte, primary, Amorim, Sandy, additional, Perrot, Aurore, additional, Quittet, Philippe, additional, Cornillon, Jerome, additional, Chaoui, Driss, additional, Marolleau, Jean P., additional, Oberic, Lucie, additional, Le Du, Katell, additional, Fornecker, Luc‐Matthieu, additional, Tournilhac, Olivier, additional, Veillard, Anne S., additional, Chaillol, Isabelle, additional, Robin, Marie, additional, Tamburini, Jérôme, additional, and Brice, Pauline, additional

Published
2018
Full Text
View/download PDF

25. The value of molecular techniques to diagnose Ureaplasma urealyticum and Nocardia farcinica pleuropneumonia in a patient with diffuse large B-cell lymphoma

Author

Canouï, Etienne, primary, Blanc, Kim, additional, Loubinoux, Julien, additional, Valade, Sandrine, additional, Hamard, Cécile, additional, Lefebvre, Aurélie, additional, Amorim, Sandy, additional, Bébéar, Cécile, additional, Rodriguez-Nava, Veronica, additional, Lebeaux, David, additional, Launay, Odile, additional, Alifano, Marco, additional, Rabbat, Antoine, additional, and Kernéis, Solen, additional

Published
2017
Full Text
View/download PDF

28. Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?

Author

Bigenwald, Camille, primary, Harel, Stéphanie, additional, Chevignon, Florian, additional, Roos-Weil, Damien, additional, Bernard, Olivier A., additional, Amorim, Sandy, additional, Brice, Pauline, additional, Adès, Lionel, additional, Nloga, Anne Marie, additional, Sébert, Marie, additional, Braun, Thorsten, additional, Eclache, Virginie, additional, Thieblemont, Catherine, additional, and Fenaux, Pierre, additional

Published
2016
Full Text
View/download PDF

29. Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study

Author

Fleury, Isabelle, Amorim, Sandy, Mounier, Nicolas, Coiffier, Bertrand, Dupuis, Jehan, Tilly, Hervè, Mazari, Mohamed A, Filliatre, Lauriane, Bri?re, Josette, Brice, Pauline, De Kerviler, Eric, Thieblemont, Catherine, Brière, Josette, Université Paris Diderot - Paris 7 (UPD7), Laboratoire de Parasitologie-Mycologie [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre de Recherche en Cancérologie de Lyon (CRCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de Mathématiques de Toulouse UMR5219 (IMT), Université Toulouse 1 Capitole (UT1)-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UPS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-PRES Université de Toulouse-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Groupe d'étude des proliférations lymphoïdes (GPL), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Sciences Moléculaires de Marseille (ISM2), Aix Marseille Université (AMU)-Ecole Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS), Université Grenoble Alpes (UGA), Laboratoire de Psychologie et NeuroCognition (LPNC), Université Pierre Mendès France - Grenoble 2 (UPMF)-Université Joseph Fourier - Grenoble 1 (UJF)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Service de radiologie [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Hôpital Saint-Louis, and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)

Subjects
Male, Cancer Research, CHOP, Gastroenterology, Central Nervous System Neoplasms, International Prognostic Index, Prednisone, immune system diseases, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Medicine, Aged, 80 and over, B-Lymphocytes, Lymphoma, Non-Hodgkin, Disease Management, Hematology, Middle Aged, Prognosis, Combined Modality Therapy, Survival Rate, Oncology, Vincristine, B-Cell Non-Hodgkin Lymphoma, Rituximab, Female, management, medicine.drug, central nervous system relapse, Adult, medicine.medical_specialty, lymphoma, [SDV.CAN]Life Sciences [q-bio]/Cancer, Young Adult, Spinal cord compression, Internal medicine, Humans, Cyclophosphamide, Aged, Neoplasm Staging, Retrospective Studies, business.industry, medicine.disease, Surgery, Lymphoma, Doxorubicin, Cranial Irradiation, Neoplasm Recurrence, Local, business, Spinal Cord Compression, Follow-Up Studies
Abstract

International audience; Initial spinal cord compression (ISCC) in B-cell non-Hodgkin lymphoma (NHL) is rarely present at diagnosis. We performed a multicenter retrospective analysis of 66 patients with ISCC, including diffuse large B-cell (DLBCL) (70%), follicular (20%), small lymphocytic (6%), marginal zone (2%) and B-cell unclassified (2%) lymphomas, with the aim of describing their management and outcomes, as well as the occurrence of central nervous system (CNS) relapses. All but two patients received cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or CHOP-like regimens, with rituximab in 61% of cases. Forty-six patients received CNS prophylaxis. The 5-year overall survival and progression-free survival were 78% and 65% for DLBCL, and 60% and 48% for indolent lymphomas, respectively. CNS relapses occurred in four (6%) patients, all with DLBCL and all in the cerebellum. Initial decompressive procedures, intradural involvement, cerebrospinal fluid infiltration and lack of CNS prophylaxis did not influence survival. Adverse prognostic factors were male sex, poor performance status, elevated lactate dehydrogenase and high age-adjusted international prognostic index.

Published
2014

30. Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases

Author

Gac, Anne-Claire, primary, Azar, Nabih, additional, Daguindau, Etienne, additional, Cartron, Guillaume, additional, Fornecker, Luc M., additional, Gyan, Emmanuel, additional, Broussais-Guillaumot, Florence, additional, Garidi, Reda, additional, Choufi, Bachra, additional, Chantepie, Sylvain P., additional, Béné, Marie-Christine, additional, Guiéze, Romain, additional, Bijou, Fontanet, additional, Gressin, Remy, additional, Amorim, Sandy, additional, and Damaj, Gandhi, additional

Published
2016
Full Text
View/download PDF

34. Are Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Occurring during the Course of Lymphoma (Ly) Always Therapy Related?

Author

Bigenwald, Camille, primary, Harel, Stephanie, additional, Chevillon, Florian, additional, Roos-Weil, Damien, additional, Bernard, Olivier A., additional, Amorim, Sandy, additional, Brice, Pauline, additional, Lionel, Ades, additional, Nloga, Anne Marie, additional, Sébert, Marie, additional, Braun, Thorsten, additional, Eclache, Virginie, additional, Thieblemont, Catherine, additional, and Fenaux, Pierre, additional

Published
2015
Full Text
View/download PDF

35. Yttrium-90 Ibritumomab Tiuxetan Is Feasible and Efficient in Unselected Patients. Definitive Results of a Large Retrospective Phase IV Study

Author

Richez, Valentine, primary, Abraham, Julie, additional, Amorim, Sandy, additional, Herbaux, Charles, additional, Philippe, Laure, additional, Andre, Marc, additional, Parcelier, Anne, additional, Fruchart, Christophe, additional, Bouabdallah, Krimo, additional, Cornillon, Jérôme, additional, Cherrier, Sigrid, additional, Salvado, Clementine, additional, Drenou, Bernard, additional, Oberic, Lucie, additional, Quittet, Philippe, additional, Venton, Geoffroy, additional, Calmettes, Claire, additional, Chebrek, Safia, additional, Rossi, Cedric, additional, Campidelli, Arnaud, additional, Lioure, Bruno, additional, Auger, Sophie, additional, Altounian, Lucille, additional, Mineur, Philippe, additional, Woff, Erwin, additional, and Peyrade, Frederic, additional

Published
2015
Full Text
View/download PDF

38. A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies

Author

Thieblemont, Catherine, primary, Stathis, Anastasios, additional, Inghirami, Giorgio, additional, Karlin, Lionel, additional, Morschhauser, Franck, additional, Gleeson, Mary, additional, Broussais, Florence, additional, Amorim, Sandy, additional, Salles, Gilles, additional, Facon, Thierry, additional, Cunningham, David, additional, Vey, Norbert, additional, Bourdel, Fabrice, additional, Herait, Patrice, additional, and Zucca, Emanuele, additional

Published
2014
Full Text
View/download PDF

43. A multicenter study of 66 patients with spinal cord compression at diagnosis of B-cell non-Hodgkin lymphoma.

Author

Fleury, Isabelle, primary, Amorim, Sandy, additional, Mounier, Nicolas, additional, Coiffier, Bertrand, additional, Dupuis, Jehan, additional, Tilly, Herve, additional, Mazari, Mohamed Amine, additional, Filliatre, Lauriane, additional, Briere, Josette, additional, Brice, Pauline, additional, de Kerviler, Eric, additional, and Thieblemont, Catherine, additional

Published
2014
Full Text
View/download PDF

44. Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study.

Author

Fleury, Isabelle, Amorim, Sandy, Mounier, Nicolas, Coiffier, Bertrand, Dupuis, Jehan, Tilly, Hervè, Mazari, Mohamed A., Filliatre, Lauriane, Brière, Josette, Brice, Pauline, de Kerviler, Eric, and Thieblemont, Catherine

Subjects
*B cells, *HODGKIN'S disease, *SPINAL cord, *HUMORAL immunity, *LYMPHOCYTES
Abstract

Initial spinal cord compression (ISCC) in B-cell non-Hodgkin lymphoma (NHL) is rarely present at diagnosis. We performed a multicenter retrospective analysis of 66 patients with ISCC, including diffuse large B-cell (DLBCL) (70%), follicular (20%), small lymphocytic (6%), marginal zone (2%) and B-cell unclassified (2%) lymphomas, with the aim of describing their management and outcomes, as well as the occurrence of central nervous system (CNS) relapses. All but two patients received cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or CHOP-like regimens, with rituximab in 61% of cases. Forty-six patients received CNS prophylaxis. The 5-year overall survival and progression-free survival were 78% and 65% for DLBCL, and 60% and 48% for indolent lymphomas, respectively. CNS relapses occurred in four (6%) patients, all with DLBCL and all in the cerebellum. Initial decompressive procedures, intradural involvement, cerebrospinal fluid infiltration and lack of CNS prophylaxis did not influence survival. Adverse prognostic factors were male sex, poor performance status, elevated lactate dehydrogenase and high age-adjusted international prognostic index. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

45. Outcomes after intensive care unit admission of patients with newly diagnosed lymphoma.

Author

Algrin, Caroline, Faguer, Stanislas, Lemiale, Virginie, Lengliné, Etienne, Boutboul, David, Amorim, Sandy, Galicier, Lionel, Canet, Emmanuel, Thieblemont, Catherine, and Azoulay, Elie

Subjects
INTENSIVE care units, HOSPITAL admission & discharge, LYMPHOMA diagnosis, CANCER chemotherapy, ARTIFICIAL respiration, ADULT respiratory distress syndrome, TUMOR lysis syndrome
Abstract

No data are available on outcomes of patients with lymphoma requiring intensive care unit (ICU) admission. We retrospectively studied 190 patients admitted to our ICU between 2000 and 2010, before or during the first chemotherapy course for lymphoma. Reasons for ICU admission were renal failure (36%), shock (28%), respiratory failure (26%), coma (22%) and monitoring (12%). Mechanical ventilation was needed in 45% of patients, dialysis in 41% and vasoactive drugs in 30%. ICU, hospital and 1-year mortality rates were 22%, 37% and 51%. By multivariate analysis, factors associated with higher hospital mortality were age > 50 years (odds ratio [OR], 2.23; 95% confidence interval [CI], 1.02-4.9), poor performance status (OR, 3.36; 95% CI, 1.47-6.54), high Sequential Organ Failure Assessment (SOFA) score (OR, 1.15/point; 95% CI, 1.04-1.27), hemophagocytic syndrome (OR, 2.57; 95% CI, 1.03-6.40), Burkitt lymphoma (OR, 3.36; 95% CI, 1.38-8.19) and primary cerebral lymphoma (OR, 7.32; 95% CI, 1.06-50.54). Admission after 2004 was associated with better survival (OR, 0.35; 95% CI, 0.15-0.78). [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

46. Rituximab- ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy.

Author

Garciaz, Sylvain, Harel, Stephanie, Amorim, Sandy, Bouabdallah, Réda, Thieblemont, Catherine, and Brice, Pauline

Subjects
HODGKIN'S disease treatment, COMBINATION drug therapy, RITUXIMAB, THERAPEUTIC use of monoclonal antibodies, ANTINEOPLASTIC agents
Abstract

The article discusses the results of a retrospective cohort of patients with nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), ineligible for radiation therapy, treated with the monoclonal antibody Rituximab and standard adriamycin, bleomycin, vinblastine, dacarbazine (ABVD). Topics covered include the effectivity and safety of combination drug therapy with Rituximab and ABVD, risk of pulmonary events, and Rituximab's use as a single agent in front-line therapy in advanced NLPHL.

Published
2016
Full Text
View/download PDF

47. Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.

Author

Carras S, Torroja A, Emadali A, Montaut E, Daguindau N, Tempescul A, Moreau A, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Barbieux S, Corm S, Banos A, Fouillet L, Dupuis J, Macro M, Fleury J, Jardin F, Sarkozy C, Damaj G, Feugier P, Fornecker LM, Chabrot C, Dorvaux V, Bouabdallah K, Amorim S, Garidi R, Voillat L, Joly B, Morineau N, Moles MP, Zerazhi H, Fontan J, Arkam Y, Alexis M, Delwail V, Vilque JP, Ysebaert L, Burroni B, Callanan M, Le Gouill S, and Gressin R

Subjects
Humans, Aged, Female, Male, Aged, 80 and over, Prognosis, Rituximab therapeutic use, Rituximab administration & dosage, Treatment Outcome, Bendamustine Hydrochloride administration & dosage, Bendamustine Hydrochloride therapeutic use, Dexamethasone therapeutic use, Dexamethasone administration & dosage, Doxorubicin therapeutic use, Doxorubicin administration & dosage, Lymphoma, Mantle-Cell drug therapy, Lymphoma, Mantle-Cell genetics, Lymphoma, Mantle-Cell mortality, Lymphoma, Mantle-Cell pathology, Tumor Suppressor Protein p53 genetics, Mutation, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Hypoalbuminemia etiology
Abstract

Between 2011 and 2012, a phase II trial evaluated the use of the RiBVD (rituximab, bendamustine, velcade and dexamethasone) combination as first-line treatment for mantle cell lymphoma (MCL) patients over the age of 65. We have now re-examined the classic prognostic factors, adding an assessment of TP53 mutation status. Patients (N=74; median age 73 years) were treated with the RiBVD combination. Median progression-free survival (mPFS) was 79 months and median overall survival (mOS) was 111 months. TP53 mutation status was available for 54/74 (73%) patients. TP53 mutations (TP53mt) were found in 12 patients (22.2%). In multivariate analysis, among the prognostic factors (PF) evaluated, only TP53mt and an albumin level (Alb) 3.6 g/dL were independently associated with a shorter mPFS. A hazard ratio (HR) of 3.16 (1.3-9.9, P=0.014) was obtained for TP53mt versus TP53 wild-type (wt), and 3.6 (1.39-9.5, P=0.009) for Alb <3.6 g/dL versus Alb ≥3.6 g/dL. In terms of mOS, multivariate analysis identified three PF: TP53mt (HR: 5.9 [1.77-19.5, P=0.004]), Alb <3.6 g/dL (HR: 5.2 [1.46- 18.5, P=0.011]), and ECOG=2 (HR: 3.7 [1.31-10.6, P=0.014]). Finally, a score combining TP53 status and Alb distinguished three populations based on the presence of 0, 1, or 2 PF. For these populations, mPFS was 7.8 years, 28 months, and 2.5 months, respectively. Our prolonged follow-up confirmed the efficacy of the RiBVD regimen, comparing it favorably to other regimens. TP53mt and hypoalbuminemia emerge as strong PF that can be easily integrated into prognostic scores for older adult patients with MCL.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results